Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCH NASDAQ:DRIO NASDAQ:HIND NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$0.70+0.3%$0.71$0.36▼$1.91$53.59M1.92593,339 shs75,852 shsDRIODarioHealth$7.99+7.2%$8.52$5.93▼$17.74$58.33M1.0914,647 shs5,537 shsHINDVyome$2.07-1.0%$2.43$1.75▼$46.60$14.53M1.38631,252 shs30,854 shsNSPRInspireMD$1.10-6.0%$1.55$1.02▼$2.93$51.58M0.83169,724 shs573,609 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical0.00%+4.13%-8.90%+14.61%-49.74%DRIODarioHealth0.00%-2.05%-13.48%-33.93%-51.55%HINDVyome0.00%-8.84%-7.98%-5.31%+195,999,900.00%NSPRInspireMD0.00%-4.96%-25.32%-29.88%-57.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$0.70+0.3%$0.71$0.36▼$1.91$53.59M1.92593,339 shs75,852 shsDRIODarioHealth$7.99+7.2%$8.52$5.93▼$17.74$58.33M1.0914,647 shs5,537 shsHINDVyome$2.07-1.0%$2.43$1.75▼$46.60$14.53M1.38631,252 shs30,854 shsNSPRInspireMD$1.10-6.0%$1.55$1.02▼$2.93$51.58M0.83169,724 shs573,609 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical0.00%+4.13%-8.90%+14.61%-49.74%DRIODarioHealth0.00%-2.05%-13.48%-33.93%-51.55%HINDVyome0.00%-8.84%-7.98%-5.31%+195,999,900.00%NSPRInspireMD0.00%-4.96%-25.32%-29.88%-57.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCHEnvoy Medical 2.25Hold$6.00760.83% UpsideDRIODarioHealth 2.25Hold$35.00338.05% UpsideHINDVyome 2.50Moderate Buy$15.00624.64% UpsideNSPRInspireMD 3.00Buy$4.50309.09% UpsideCurrent Analyst Ratings BreakdownLatest HIND, DRIO, NSPR, and COCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/4/2026HINDVyome Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026HINDVyome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/24/2026COCHEnvoy Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/1/2026COCHEnvoy Medical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/31/2026COCHEnvoy Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.503/20/2026DRIODarioHealth Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $10.002/24/2026NSPRInspireMD Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.002/24/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCHEnvoy Medical$241K222.35N/AN/A($0.42) per share-1.66DRIODarioHealth$22.36M2.61N/AN/A$10.05 per share0.80HINDVyome$320K45.41N/AN/A$0.67 per share3.09NSPRInspireMD$8.98M5.74N/AN/A$1.83 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCHEnvoy Medical-$23.76M-$1.22N/AN/AN/A-9,857.26%N/A-256.65%5/7/2026 (Estimated)DRIODarioHealth-$41.71M-$10.43N/AN/AN/A-186.57%-59.48%-36.94%5/13/2026 (Estimated)HINDVyome-$10.26M-$125.20N/AN/AN/A-270.58%-279.99%-142.04%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest HIND, DRIO, NSPR, and COCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DRIODarioHealth-$1.48N/AN/AN/A$5.46 millionN/A5/7/2026N/ACOCHEnvoy Medical-$0.14N/AN/AN/A$0.10 millionN/A3/23/2026Q4 2025COCHEnvoy Medical-$0.24-$0.26-$0.02-$0.26$0.03 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOCHEnvoy MedicalN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/AHINDVyomeN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCHEnvoy MedicalN/A0.540.41DRIODarioHealth0.453.763.30HINDVyomeN/A1.991.99NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCHEnvoy Medical8.59%DRIODarioHealth33.39%HINDVyome22.06%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCOCHEnvoy Medical7.10%DRIODarioHealth3.50%HINDVyome33.00%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCHEnvoy Medical3476.88 million71.42 millionNot OptionableDRIODarioHealth2007.30 million7.05 millionNo DataHINDVyome507.02 million4.70 millionN/ANSPRInspireMD5046.89 million18.33 millionOptionableHIND, DRIO, NSPR, and COCH HeadlinesRecent News About These CompaniesInspireMD Inc.: InspireMD Reports First Quarter 2026 Financial Results3 hours ago | finanznachrichten.deInspireMD (NSPR) Q4 2025 Earnings Transcript3 hours ago | fool.comInspireMD, Inc. (NSPR) Q1 2026 Earnings Call TranscriptMay 4 at 7:02 PM | seekingalpha.comInspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue EstimatesMay 4 at 6:50 PM | zacks.comInspireMD Reports First Quarter 2026 Financial ResultsMay 4 at 4:05 PM | globenewswire.comInspireMD recalls CGuard Prime 135 cm stent delivery system in US, gets nod to study neuroprotection techMay 2 at 8:55 AM | massdevice.comNSPR rallies after hours on FDA green light for key stroke-prevention trial despite withdrawn annual guidanceMay 2 at 8:55 AM | msn.comInspireMD Recalls CGuard Prime Delivery System, Pauses U.S. LaunchMay 1, 2026 | tipranks.comInspireMD Receives FDA Approval for CGUARDIANS III Pivotal Study of SwitchGuard Neuro Protection SystemMay 1, 2026 | quiverquant.comQInspireMD Reports 53% Year-Over-Year Unit Sales Growth Amid Anticipated FDA Approvals and Voluntary Recall of CGuard Prime 135 cm Delivery SystemMay 1, 2026 | quiverquant.comQInspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection SystemMay 1, 2026 | globenewswire.comInspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery SystemMay 1, 2026 | globenewswire.comInspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?May 1, 2026 | marketbeat.comInspireMD to Announce First Quarter 2026 Financial ResultsApril 27, 2026 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)April 14, 2026 | prnewswire.comAfter Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)April 8, 2026 | zacks.comInspireMD (NYSE:NSPR) Trading Down 6.7% - What's Next?April 8, 2026 | marketbeat.comInspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare ConferenceMarch 31, 2026 | globenewswire.comInspireMD Reports Strong Q4 2025 Growth and ExpansionMarch 19, 2026 | theglobeandmail.comInspireMD targets $13M–$15M in 2026 revenue as CGuard Prime gains U.S. tractionMarch 18, 2026 | seekingalpha.comInspireMD tops Q4 estimates as revenue jumps, shares rise in premarket tradingMarch 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026What's Behind D-Wave's Spring Rally, and Will It Continue?By Nathan Reiff | April 20, 2026Bloom Energy May Be Solving AI’s Biggest Power ProblemBy Thomas Hughes | May 1, 2026Is This Pre-IPO AI Robotics Company the Next Big Defense Play?By Bridget Bennett | April 30, 2026HIND, DRIO, NSPR, and COCH Company DescriptionsEnvoy Medical NASDAQ:COCH$0.70 +0.00 (+0.32%) Closing price 04:00 PM EasternExtended Trading$0.68 -0.02 (-3.01%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.DarioHealth NASDAQ:DRIO$7.99 +0.54 (+7.25%) Closing price 04:00 PM EasternExtended Trading$8.01 +0.02 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Vyome NASDAQ:HIND$2.07 -0.02 (-0.96%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.06 (+2.66%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.InspireMD NYSE:NSPR$1.10 -0.07 (-5.98%) Closing price 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.82%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
